Leerink Affirms Ironwood Pharma (IRWD) at 'Market Perform'; No Catalyst Seen in Next 12 - 18 Months
Leerink affirms Ironwood Pharma (Nasdaq: IRWD) with a Market Perform rating and $12 price target following Q3 results issued Tuesday ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)